《华盛顿邮报》：没有冠状病毒的岛国帕劳很快就会为几乎所有人民接种疫苗
人口接近 18,000 人的小岛国帕劳已成功摆脱了 COVID-19 疾病的困扰。作为与美国“自由联合”协议的一部分，帕劳可以获得 Moderna COVID-19 疫苗，并计划到 2021 年 4 月实现几乎所有人口的免疫。
要了解更多信息，请点击以下链接：
《华盛顿邮报》：没有冠状病毒的岛国帕劳很快就会为几乎所有人民接种疫苗
保存我们首个 CVU 迷你系列活动的日期：2021 年 2 月 8 日
MVEC 很高兴地宣布我们首届 CVU 迷你系列活动的详细信息！
什么时候： 2021 年 2 月 8 日
时间: 7:00-8:30 下午
主题将包括:
- COVID-19 疫苗概况（阿斯利康/辉瑞）
- 维多利亚州 COVID-19 疫苗概况扫描
- 维多利亚州 COVID-19 疫苗推出信息
成本: 自由的
更多详细信息和注册信息将很快通过我们的 事件 页。请注意，本次活动将通过 Zoom 虚拟方式举行。
活动结束后，我们的网站上还将提供视频记录。
时代报：我们不能推迟疫苗的推出，冒着冬季患重大疾病的风险
许多科学家呼吁暂停拟议中的 COVID-19 疫苗推广，这是一个令人担忧的问题。
The following article suggests that Australia's initial public health goal should be a rapid vaccine rollout and not herd immunity, in order to limit further risk of major illness. In order to achieve a rapid rollout, both the AstraZeneca and Pfizer COVID-19 vaccines are needed. Recent modelling suggests that vaccination will most likely shift SARS-CoV-2 from a virus causing major disease burden, to a relatively benign coronavirus causing the common cold.
要完整阅读文章，请点击以下链接：
高峰机构支持澳大利亚的 COVID-19 疫苗战略
在 2020 年 1 月 13 日发布的声明中， 澳大利亚传染病协会 (ASID)， 这 澳大利亚感染预防与控制学院 (ACIPC) 和 澳大利亚公共卫生协会 (PHAA) have shown support for the Commonwealth Government's COVID-19 vaccine strategy. The statement suggests that recent media reports surrounding concerns for the ability of any vaccine to create herd immunity is unjustified and reinforces that the public should have confidence in the approach being taken to provide COVID-19 vaccines to Australians.
要完整阅读该声明，请点击以下链接：
MVEC eLearning: Shoulder injury related to vaccine administration (SIRVA)
MVEC are excited to launch the next of our eLearning packages. Our eLearning packages are designed to allow immunisation providers consolidate and evaluate their technical skills. Targeted resources are available to assist with our eLearning and a certificate of completion will be made available upon completion of the corresponding eLearning quiz.
疫苗接种相关的肩伤 (SIRVA) demonstrates what SIRVA is, how it can be prevented, how SIRVA can be diagnosed and treated, as well as how to report SIRVA.
You can access Shoulder injury related to vaccine administration (SIRVA) via our MVEC 教育门户 或通过以下链接：
Zostavax vaccine: Safety advisory - risk of disseminated varicella zoster virus (vaccine strain) infection
Following a third report of fatal disseminated vaccine strain varicella-zoster virus infection following Zostavax administration, the Therapeutic Goods Administration (TGA) is reminding health professionals that Zostavax should not be used in people with compromised immune function.
Further details on the alert can be seen here:
Zostavax vaccine: Safety advisory
For more information on Zostavax® and access to the Zostavax® GP decision aid please review the MVEC pages below:
微血管内皮细胞： 带状疱疹
微血管内皮细胞： Zoster vaccine (Zostavax®) FAQ’s
New immunisation reference page: COVID-19 vaccine platforms
Multiple different vaccine technologies or 'platforms' are being trialled by the over 200 COVID-19 vaccine candidates currently in development in an effort to limit the spread of the SARS-CoV-2 virus. Our new reference page provides a summary of the different approaches, including the newer or 'novel' platforms, and highlights the COVID-19 vaccine candidates in the most advanced stages of clinical trials.
To learn more follow the link below:
MVEC: COVID-19 vaccine platforms
FDA report reveals phase 3 clinical trial data for the Moderna COVID-19 vaccine candidate
In preparation for a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC), the FDA has made public the interim results of phase 3 clinical trials for the Moderna COVID-19 vaccine candidate. This meeting will discuss the Emergency Use Authorisation (EUA) application and determine any recommendations for approval.
Phase 3 clinical trials for this vaccine were spread across 99 sites in the United States and participants were aged 18 years or older. The Moderna vaccine utilises a messenger RNA (mRNA) platform. Interim results show an acceptable safety profile. Following the administration of 2 doses, 28 days apart, it is reported that this vaccine has an efficacy rate of 94.5%.
To read the document in full please refer to the link below:
New immunisation reference page: Hypotonic-hyporesponsive episode (HHE)
A hypotonic-hyporesponsive episode (HHE) is the sudden onset of muscle limpness, reduced responsiveness or unresponsiveness, and pallor or cyanosis occurring after vaccination in early childhood. The episode usually occurs within 48 hours of vaccination and resolves spontaneously without treatment. Our new reference page describes HHE, its incidence and its impact on future vaccination.
To read more please follow the link below:
MVEC: Hypotonic-hyporesponsive episode (HHE)